Preventive effects of a Kampo medicine, Shosaikoto, on inflammatory responses in LPS-treated human gingival fibroblasts.
In the present study, we investigated the anti-inflammatory effects of a Kampo medicine Shosaikoto (TJ-9) using in vitro periodontal disease model, in which human gingival fibroblasts (HGFs) treated with lipopolysaccharide (LPS) from Porphyromonas gingivalis (PgLPS) produce IL-6, IL-8 and prostaglandin E2 (PGE2). Treatment with PgLPS (10 ng/ml), TJ-9 (up to 1 mg/ml) and their combinations for 24 h did not affect the viability of HGFs. Moreover, TJ-9 did not alter LPS-induced IL-6 and IL-8 productions. However, TJ-9 significantly suppressed LPS-induced PGE2 production in a dose-dependent manner but TJ-9 alone did not affect basal PGE2 level. Western blotting demonstrated that TJ-9 decreased cyclooxygenase-2 (COX-2) expression in a dose-dependent manner but not phospholipase A2. Moreover, TJ-9 selectively and dose-dependently inhibited COX-2 activity. These results suggest that TJ-9 decreased PGE2 production by inhibition of both COX-2 expression and activity and that TJ-9 may be useful to improve gingival inflammation in periodontal disease.
Ara
Toshiaki
T
Department of Pharmacology, Matsumoto Dental University, Shiojiri, Nagano, Japan.
Maeda
Yoshihiro
Y
Fujinami
Yoshiaki
Y
Imamura
Yasuhiro
Y
Hattori
Toshimi
T
Wang
Pao-Li
PL
D000894:Anti-Inflammatory Agents, Non-Steroidal; D015153:Blotting, Western; D002470:Cell Survival / Q000187:drug effects; D051545:Cyclooxygenase 1 / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism; D015232:Dinoprostone / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004365:Drugs, Chinese Herbal / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D005347:Fibroblasts / Q000187:drug effects*; D005881:Gingiva / Q000166:cytology* / Q000187:drug effects*; D005891:Gingivitis / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007202:Indicators and Reagents; D015850:Interleukin-6 / Q000096:biosynthesis; D016209:Interleukin-8 / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D020835:Medicine, Kampo; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D016966:Porphyromonas gingivalis / Q000737:chemistry; D013778:Tetrazolium Salts; D013844:Thiazoles
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004365:Drugs, Chinese Herbal; D007202:Indicators and Reagents; D015850:Interleukin-6; D016209:Interleukin-8; D008070:Lipopolysaccharides; D013778:Tetrazolium Salts; D013844:Thiazoles; C461321:shosaikoto-go-keishika-shakuyakuto; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C022616:thiazolyl blue; D015232:Dinoprostone